Summary: Under EU FMD, US DSCSA, and parallel regimes elsewhere, prescription packs often carry a unique serial alongside GTIN, expiry, and batch in a 2D symbol (commonly Data Matrix). Downstream partners scan at dispense or distribution to verify authenticity against government or industry hubs. The goal is to shrink counterfeit ingress and enable targeted recalls.
Serialization is a chain: manufacturer aggregation (bundle → case → pallet) must reconcile with what wholesalers and pharmacies see. A single mis-encoded character can orphan thousands of salable units.
Operational scan points
- Line packaging: camera verifiers reject poor print before cartons seal.
- Warehouse: handhelds confirm case IDs against ASN data.
- Pharmacy: integration with PMR systems; offline queues if hubs hiccup.
Lessons for other regulated industries
Cosmetics and supplements increasingly borrow serialization patterns for grey-market control. The through-line is deterministic batch data generation: no manual edits to serial ranges, cryptographic randomness where required, and audit logs that regulators can read.
Disclaimer
This article is informational, not legal advice. Always validate workflows with qualified regulatory affairs counsel for your market.
Starting points
- EMA / national bodies for EU FMD implementation updates.
- FDA DSCSA resources for US supply-chain milestones.
- GS1 Healthcare for identification standards.